i
Phase II, open-label study to assess the safety and immunogenicity of Fluzone® High-Dose Quadrivalent (Influenza Vaccine), 2021–2022 Formulation and a third dose of mRNA-1273 COVID-19 vaccine (Moderna) administered either concomitantly or singly in adults 65 years of age and older previously vaccinated with a 2-dose schedule of mRNA-1273 vaccine
-
October 20, 2021
Series: ACIP meeting Influenza
Details:
-
Personal Author:
-
Corporate Authors:
-
Conference Authors:
-
Subjects:
-
Series:
-
Document Type:
-
Name as Subject:
-
Genre:
-
Collection(s):
-
Main Document Checksum:
-
File Type:
Supporting Files
-
No Additional Files
More +